» Articles » PMID: 38612708

Association Between Parkinson's Disease and Cancer: New Findings and Possible Mediators

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2024 Apr 13
PMID 38612708
Authors
Affiliations
Soon will be listed here.
Abstract

Epidemiological evidence points to an inverse association between Parkinson's disease (PD) and almost all cancers except melanoma, for which this association is positive. The results of multiple studies have demonstrated that patients with PD are at reduced risk for the majority of neoplasms. Several potential biological explanations exist for the inverse relationship between cancer and PD. Recent results identified several PD-associated proteins and factors mediating cancer development and cancer-associated factors affecting PD. Accumulating data point to the role of genetic traits, members of the synuclein family, neurotrophic factors, the ubiquitin-proteasome system, circulating melatonin, and transcription factors as mediators. Here, we present recent data about shared pathogenetic factors and mediators that might be involved in the association between these two diseases. We discuss how these factors, individually or in combination, may be involved in pathology, serve as links between PD and cancer, and affect the prevalence of these disorders. Identification of these factors and investigation of their mechanisms of action would lead to the discovery of new targets for the treatment of both diseases.

Citing Articles

Causal association between Parkinson's disease and cancer: a bidirectional Mendelian randomization study.

Tang C, Fu P, Lin L, Zhou H, Huang Y, Li Y Front Aging Neurosci. 2024; 16:1432373.

PMID: 39563740 PMC: 11573767. DOI: 10.3389/fnagi.2024.1432373.


Interfering with aggregated α-synuclein in advanced melanoma leads to a major upregulation of MHC class II proteins.

Fokken C, Silbern I, Shomroni O, Pan K, Ryazanov S, Leonov A Melanoma Res. 2024; 34(5):393-407.

PMID: 38950202 PMC: 11361348. DOI: 10.1097/CMR.0000000000000982.

References
1.
Peters O, Shelkovnikova T, Highley J, Cooper-Knock J, Hortobagyi T, Troakes C . Gamma-synuclein pathology in amyotrophic lateral sclerosis. Ann Clin Transl Neurol. 2015; 2(1):29-37. PMC: 4301672. DOI: 10.1002/acn3.143. View

2.
Ye Q, Wang T, Peng Y, Xie J, Feng B, Qiu M . Expression of alpha-, beta- and gamma-synuclein in colorectal cancer, and potential clinical significance in progression of the disease. Oncol Rep. 2010; 23(2):429-36. View

3.
Liu J, Zhang C, Zhao Y, Yue X, Wu H, Huang S . Parkin targets HIF-1α for ubiquitination and degradation to inhibit breast tumor progression. Nat Commun. 2017; 8(1):1823. PMC: 5703960. DOI: 10.1038/s41467-017-01947-w. View

4.
Nair J, Nair A, Veerappan S, Sen D . Translatable gene therapy for lung cancer using Crispr CAS9-an exploratory review. Cancer Gene Ther. 2019; 27(3-4):116-124. DOI: 10.1038/s41417-019-0116-8. View

5.
Fujiwara H, Hasegawa M, Dohmae N, Kawashima A, Masliah E, Goldberg M . alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol. 2002; 4(2):160-4. DOI: 10.1038/ncb748. View